Description: Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Home Page: www.beamtx.com
BEAM Technical Analysis
238 Main Street
Cambridge,
MA
02142
United States
Phone:
857 327 8775
Officers
| Name | Title |
|---|---|
| Mr. John M. Evans M.B.A. | CEO & Director |
| Dr. Giuseppe Ciaramella Ph.D. | Pres & Chief Scientific Officer |
| Ms. Terry-Ann Burrell M.B.A. | CFO & Treasurer |
| Dr. Feng Zhang Ph.D. | Co-Founder |
| Dr. David R. Liu Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Nicole Gaudelli Ph.D. | Co-Founder |
| Dr. Alexis Komor Ph.D. | Co-Founder |
| Ms. Suzanne Fleming | Chief Accounting Officer |
| Mr. Brian Riley | Sr. VP of Technical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.4265 |
| Price-to-Sales TTM: | 32.425 |
| IPO Date: | 2020-02-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 507 |